Exchange: NASDAQ·Updated 07:30 PM EST

SCNX News

News
all
press releases
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.read more...
Benzinga
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.read more...
Benzinga
More News
For children who cannot swallow tablets or need individualized doses, the pharmacy often becomes the final step in manufacturing their medicine. Ready-to-use liquid formulations can remove that preparation burden, but hospital formulary access is an important step toward getting them into routine care.Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are climbing Friday after the company announced that Arbli™, its losartan potassium oral suspension, has been added to the formularies of three leading U.S. pediatric academic medical centers and hospitals. The institutions specialize in ...
AllPennyStocks.com
For children who cannot swallow tablets or need individualized doses, the pharmacy often becomes the final step in manufacturing their medicine. Ready-to-use liquid formulations can remove that preparation burden, but hospital formulary access is an important step toward getting them into routine care.Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are climbing Friday after the company announced that Arbli™, its losartan potassium oral suspension, has been added to the formularies of three leading U.S. pediatric academic medical centers and hospitals. The institutions specialize in ...
AllPennyStocks.com
SCIENTURE (NASDAQ:SCNX) is giving investors a fresh commercial catalyst as its FDA-approved Arbli oral suspension wins formulary placement at three leading U.S. pediatric academic medical centers and hospitals. The additions expand the product’s institutional footprint at a critical point in its rollout, while the company says wholesale orders have continued to increase sequentially. For a specialty pharmaceutical company focused on products addressing specific patient and healthcare-system needs, the latest formulary wins provide a tangible measure of expanding access for Arbli.
24-7 Market News
Scienture Holdings shares tumble 19% after hours following a newly announced 1-for-25 reverse stock split.read more...
Benzinga
Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventory for the commercial launch of REZENOPY.read more...
Benzinga
(RTTNews) - Shares of Scienture Holdings, Inc. (SCNX) are moving up about 31 percent on Wednesday morning trading after the company formalized multiple commercial Group Purchasing Organization...
Nasdaq News: Markets

Advertisement|Remove ads.